当前位置: X-MOL 学术Ther. Adv. Med. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
Therapeutic Advances in Medical Oncology ( IF 4.9 ) Pub Date : 2019-10-09 , DOI: 10.1177/1758835919880429
Jack J. Chan 1 , Tira J. Y. Tan 1 , Rebecca A. Dent 2, 3
Affiliation  

The past decade has witnessed concerted efforts to characterize triple-negative breast cancer (TNBC) geno-molecularly beyond its traditional immunohistochemical (IHC) definition.1–5 The discovery of candidate targetable oncogenic drivers have further promoted clinical trials of novel systemic treatments to address the unmet clinical needs of this biologically aggressive malignancy.

中文翻译:

三阴性乳腺癌的新型治疗途径:PI3K / AKT抑制,雄激素受体阻滞等

在过去的十年中,人们已经做出了共同努力,以超越传统的免疫组织化学(IHC)的定义来表征三阴性乳腺癌(TNBC)的基因-分子。1–5候选可靶向致癌驱动程序的发现进一步促进了新型全身治疗的临床试验,从而解决了这种具有生物学攻击性的恶性肿瘤的未满足的临床需求。
更新日期:2019-10-09
down
wechat
bug